Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 20, 2011

Scil Technology Establishes Protein Formulation and Manufacturing Services Unit

  • German firm Scil Technology established an independent unit, formycon, to provide services for protein drug formulation development, non-GMP and GMP drug product manufacturing and process development, quality control, and analytics. Formycon offers liquid and freeze-dried formulation expertise, in addition to liposomal and specialty formulations for topical and local administration.

    “Scil Technology has established a unique expertise working on protein formulation and analytics for clients over the past decade,” comments Christian Nafe, Scil CEO. “Therefore it is a logical step to establish formycon as a dedicated service unit for external customers and partners.”

    Scil is focused on the development of protein-based biotherapeutics for functional tissue regeneration in orthopedics and maxillofacial surgery. Lead Phase III-stage candidate MDO5 comprises a synthetic bone augmentation material coated with rhGDF-5, for use in dental implantology and the regeneration of tissue in periodontal disease. Preclinical-stage programs include the ST03, ST04, and ST05 programs, based on the cartilage growth factor, rhCD-RAP, which are focused on the repair of injury-damaged cartilage or age-related degenerative cartilage lesions.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Pharmacists and Prescription Drug Misuse Programs

Do you agree that pharmacists should make a greater effort to become more involved with prescription drug-monitoring programs?

More »